Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910975 | 0.80 | QDPR (0.47) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9654191 | 0.76 | CCR2 (0.42) | DRD2SLC18A3DRD3SLC6A4 | |
| SCHEMBL9655545 | 0.76 | SLC18A3 (0.41) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1003503 | 0.74 | DRD2 (0.73) | DRD2SLC18A3DRD3 | |
| Hydrochloric Acid SCHEMBL9811479 | 0.74 | SIGMAR1 (0.50) | DRD2SLC18A3ALDH1A1 | |
| SCHEMBL18825946 | 0.73 | KDR (0.41) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3089324 | 0.73 | — | — | |
| SCHEMBL81641 | 0.73 | DRD2 (0.54) | DRD2SLC18A3HRH3DRD3SLC6A4 | |
| SCHEMBL1812772 | 0.71 | GAA (0.53) | DRD2SLC18A3HRH3DRD3SLC6A4 | |
| SCHEMBL18193022 | 0.71 | DRD2 (0.50) | DRD2SLC18A3HRH3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | DRD2 2823/4885CHRM2 214/4885CHRM4 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.